FDA accepts AbbVie's filing for atogepant for migraine prevention
The US Food and Drug Administration has accepted its New Drug Application (NDA) for atogepant, an investigational, orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), for the preventive treatment of migraine in adults who meet criteria for episodic migraine.
The drug’s developer, AbbVie (NYSE: ABBV), anticipates a regulatory decision in late third-quarter 2021. AbbVie gained rights to atogepant along with its $63 billion acquisition of Allergan, which completed in May last year.
The NDA is supported by data from a robust clinical program evaluating the efficacy, safety and tolerability of orally-administered atogepant in nearly 2,500 patients who experience 4-14 migraine days per month including but not /limited to the pivotal Phase III ADVANCE study, the pivotal Phase IIb/III study, and the Phase III long-term safety study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze